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Glucose homeostasis and growth essentially depend on the hormone insulin engaging its receptor. Despite biochemical and
structural advances, a fundamental contradiction has persisted in the current understanding of insulin ligand–receptor
interactions. While biochemistry predicts two distinct insulin binding sites, 1 and 2, recent structural analyses have resolved
only site 1. Using a combined approach of cryo-EM and atomistic molecular dynamics simulation, we present the structure of
the entire dimeric insulin receptor ectodomain saturated with four insulin molecules. Complementing the previously described
insulin–site 1 interaction, we present the first view of insulin bound to the discrete insulin receptor site 2. Insulin binding
stabilizes the receptor ectodomain in a T-shaped conformation wherein the membrane-proximal domains converge and
contact each other. These findings expand the current models of insulin binding to its receptor and of its regulation. In
summary, we provide the structural basis for a comprehensive description of ligand–receptor interactions that ultimately
will inform new approaches to structure-based drug design.
Introduction
The insulin receptor (IR) signaling system is a key regulator of
metabolism and cellular growth. Its dysfunction is linked to
clinical manifestations such as diabetes mellitus, cancer, and
Alzheimer’s disease (Saltiel and Kahn, 2001; Belfiore and
Malaguarnera, 2011; Kleinridders et al., 2014). The IR is an ex-
tensively glycosylated disulfide-linked (αβ)2 homodimer with
a modular domain structure. Each protomer consists of an
extracellular ligand-binding α subunit and the membrane-
spanning β subunit, which also harbors the intracellular ki-
nase domain. Themodular organization of the ectodomain (ECD)
with high intrinsic flexibility poses a challenge to structural
studies of the IR, as do the branched sugars of the glycosylation
sites, and its complex ligand binding properties. Insulin binding
to the ECD concomitantly elevates the receptor’s intrinsic tyro-
sine kinase activity before cellular signal transduction (Kasuga
et al., 1982). The precise mechanism of how insulin initially
engages its receptor, as well as the associated conformational
changes leading to tyrosine kinase signaling, still remain elusive
(De Meyts, 2015; Tatulian, 2015).
Crystallography of the unliganded (i.e., apo) IR-ECD dimer
has revealed a structure resembling an inverted U or V with
respect to the membrane, placing the membrane insertion sites
∼115 Å apart from each other (McKern et al., 2006; Croll et al.,
2016). Single-particle EM of full-length IR in lipid nanodiscs
corroborated that this apo-conformation is retained in the
membrane context (Gutmann et al., 2018). Insulin binding
converts the receptor ECD into a T-like shape that draws the
membrane-proximal fibronectin domains closer together, en-
abling transmembrane signaling (Gutmann et al., 2018). Due to
the low resolution of the negative-stain 2D class averages, no
structural information about the location and number of bound
insulin molecules could be obtained. The T-shaped conformation
was confirmed shortly after by cryo-EM of the IR-ECD in com-
plex with one or two insulins bound to the N-terminal domains
(Scapin et al., 2018). However, major parts of the fibronectin
domains could not be reconstructed, preventing conclusions on
the transmembrane signaling mechanism.
In another cryo-EM approach, the soluble ECD was fused to a
C-terminal leucine zipper (termed IRΔβ-zip) in an attempt to
reduce conformational heterogeneity and to mimic membrane
anchorage, thus restoring insulin-binding properties of the
complete receptor (Hoyne et al., 2000; Weis et al., 2018).
Structural heterogeneity was further decreased by deglycosy-
lation and complexation with Fv variable domain modules of the
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anti-IR antibody 83-7. These modifications enabled the capture
of a singly liganded transition state with insulin bound to the
N-terminal region and with the fibronectin regions in a pincer-
like fashion (Weis et al., 2018).
Previous biochemical and mutagenesis experiments have
mapped two distinct binding sites, termed sites 1 and 2, on
both the IR and on insulin (De Meyts et al., 1978; De Meyts,
2015). While site 1 ligand–receptor interactions were largely
confirmed (Menting et al., 2013, 2014; Scapin et al., 2018; Weis
et al., 2018), the structural basis of site 2 interactions re-
mained controversial.
Here, by applying single-particle EM and atomistic molecular
dynamics (MD) simulations, we report the structure of the com-
plete, pseudosymmetric human IR-ECD in a T-like conformation
saturated by four insulins. We observe that the membrane-
proximal fibronectin domains converge, highlighting the cou-
pling of ligand binding and fibronectin domain interactions as
intrinsic features of the IR-ECD.While two of the observed insulin
binding sites agree with those mapped in the “head” region
(Scapin et al., 2018; Weis et al., 2018), the additional two insulin
molecules are located in the now fully resolved “stalk” regions,
providing unambiguous structural evidence for the existence and
mechanism of site 2 binding.
Results
Purification and biochemical characterization of the complete
human IR-ECD
The complete IR-ECD (IR(αβ0)2; Fig. 1 A) was produced by se-
cretion from human embryonic kidney cell–derived cells,
ensuring human-like posttranslational processing, such as
glycosylation. Purification of the recombinant protein directly
from the medium resulted in a highly pure IR-ECD that was
amenable to cryo-EM studies. SDS-PAGE confirmed a complete,
glycosylated, dimeric polypeptide composition with an appar-
ent molecular weight of 351 kD (Figs. 1 B and S1). Ligand binding
was assessed by two independent assays in solution without
diffusion constraints (Figs. 1 C and S1 F), and thus comparable
to our cryo-EM experiments. In both of these assays, ligand
labeling was entirely omitted to preserve binding properties.
First, the thermal stability of purified IR-ECD was followed by
low-volume differential intrinsic tryptophan scanning fluo-
rimetry with a temperature gradient from 20°C to 95°C (Fig. S1
F). In the absence of insulin, IR-ECD unfolds in two steps, with
transition temperatures of 58.9°C and 64.0°C. Interestingly,
insulin binding shifted the first transition temperature down to
51.1°C, implying that insulin binding leads to conformational
changes within distinct regions of the IR-ECD. Next, ligand
binding affinity measured bymicroscale thermophoresis (MST;
Seidel et al., 2013) showed an equilibrium dissociation constant
of Kd = 30.0 ± 4.3 nM (Figs. 1 C and S1 G), corresponding to a
low-affinity binding regimen. This is in good agreement with
the established concept that the soluble IR-ECD lacking mem-
brane anchorage loses high-affinity binding in the picomolar
range (Whittaker et al., 1994, 2008; Bass et al., 1996; Kiselyov
et al., 2009; Subramanian et al., 2013; De Meyts, 2015), similar
to the EGF receptor ECD (Lax et al., 1991; Ferguson et al., 2003).
Single-particle cryo-EM analysis of the IR-ECD
The IR-ECD was analyzed by single-particle cryo-EM in the
absence and presence of recombinant human insulin. Vitrifica-
tion conditions allowed cryo-EM data collection for the un-
liganded as well as for the liganded ECD. In the absence of ligand,
2D class averaging revealed considerable structural heteroge-
neity (Fig. S1 I). Although individual domains could be identified
in a subset of 2D class averages, no high-resolution features,
such as clearly identifiable, individual secondary structural el-
ements, were apparent. Consequently, attempts at reconstruct-
ing these data in 3D did not yield any subnanometer EMmaps. In
particular, the fuzzy haphazard appearance of membrane-
proximal fibronectin domains in the 2D class averages points
at considerable flexibility. This behavior of the IR-ECD in iso-
lation most likely reflects the presence of various transition
states and conformations sampled in the absence of insulin.
For cryo-EM samples of the liganded IR-ECD, saturating
amounts of 40 µM insulin were used, corresponding to a dimeric
receptor IR(αβ0)2:ligand molar ratio of ∼1:28. The rationale for
such a large ligand excess was to ensure saturation of all avail-
able insulin binding sites on the receptor and the associated
reduction of structural heterogeneity. The insulin concentration
used here is in a similar micromolar range as in previous cryo-
EM studies owing to the required IR-ECD protein concentration
for the cryo-EM analysis. Scapin et al. (2018) incubated IR-ECD
with 28 µM insulin before the EM analysis, while Weis et al.
(2018) eluted IRΔβ-zip from an insulin-affinity column with
50 µM insulin before separating the insulin-bound complex
from free insulin by gel filtration. In summary, insulin con-
centrations used throughout these studies are high compared
with physiological insulin concentrations of up to ∼5 nM, de-
pending on location and metabolic state (Horwitz et al., 1975).
For the ligand-bound IR-ECD, individual secondary structure
elements became clearly discernable after 2D classification (Figs.
1, S2, and S3). After further classification steps, 3D refinement,
and map sharpening, the 3D reconstruction of the ligand-
saturated IR-ECD reached an apparent overall resolution of 4.3
Å, as estimated by the Fourier shell correlation (FSC) of inde-
pendently refined half-maps (0.143 criterion; Rosenthal and
Henderson, 2003; Figs. S2 and S3). Our 3D reconstruction con-
firmed the T-like conformation as seen in the insulin-bound full-
length IR at low resolution by negative stain EM (Gutmann et al.,
2018). Features of the compact head containing L1, CR, and L2
domains appear better defined than the fibronectin stalks,
which exhibit more flexibility (compare local resolution esti-
mate in Fig. S3 F). Importantly, we have refrained from applying
C2 symmetry during any of the processing steps. This strategy
proved the most appropriate since initial classification in 2D and
3D indicated flexibility and a degree of asymmetry in the orga-
nization of the ligand-saturated IR-ECD (Figs. S2 and S3 B). The
asymmetry between the two IR-ECD protomers is clearly re-
flected in the final reconstruction of the saturated state and
manifests itself in the built model as described in detail below
where appropriate.
All structured domains of the IR-ECD, as well as the locali-
zation of the insulins, were unambiguously identified in our
cryo-EM density map (Figs. 1 D and 2 and Tables S1 and S2). This
Gutmann et al. Journal of Cell Biology 2
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map in combination with previously published structural in-
formation enabled us to construct a single model for IR-ECD in
complex with four insulins (Fig. 2). The single exceptions were
the intrinsically disordered insert domains (IDs) of the IR-ECD
that could only partially be modeled into certain incohesive
density features in the vicinity of the fibronectin domains. The
IDs encompass the cleavage site for furin (residues 720–723,
Arg-Lys-Arg-Arg), which processes the IR(αβ) polypeptide chain
into the IRα and IRβ chains. Thus, the ID is separated into IDα
and IDβ in the mature receptor dimer. Our data allowed us to
tentatively model the IDα loop, but we refrained from including
IDβ in the cryo-EM structure. To err on the side of caution, we
did not model the furin cleavage sites in the cryo-EM structure,
even though a noncontiguous density feature attributable to this
part of the IR-ECD α9-chain is present in the map (Table S2).
After initial rigid body docking and local flexible fitting of the
IR-ECD domains into the EM map, the resulting structure was
manually rebuilt and refined. The final model (deposited to PDB,
6SOF) conforms to commonly accepted quality indicators (Table
S1). The aforementioned pseudosymmetric organization of the
two IR-ECD protomers is clearly reflected in their substantial
model root mean square deviation (RMSD) in certain areas (e.g.,
regions of the CR domain; Fig. S4 A).
Atomistic MD simulations
To follow the dynamics of the insulin–IR-ECD interactions,
we performed atomistic MD simulations. For the sake of
completeness, we extended our experimentally determined
insulin–IR-ECD model by incorporating the previously absent
IDβ loops, as well as the N- and O-linked glycans based on
previous reports (Sparrow et al., 2007, 2008; Fig. 3 A and Ta-
bles S2 and S3). Since furin cleaves C-terminally of this se-
quence and because there is no evidence of its removal in the
secreted ECD, we also included the furin cleavage site to the
αCT helix in our simulation models. In fact, in the case of αCT9,
the furin cleavage site could be fitted into our density map;
Figure 1. IR-ECD purification and cryo-EM. (A) Scheme of IR domain architecture. L1 and L2, leucine-rich repeat domains 1 and 2; CR, cysteine-rich domain;
FnIII-1, -2, -3, fibronectin type-III domains 1, 2, 3; TM, transmembrane; JM, juxtamembrane; TK, tyrosine kinase domain; CT, C-terminal tail. The α C-terminal
regions (αCT and αCT9) are drawn in purple. Black lines indicate intersubunit disulfide bonds. A prime (9) denotes the chain, domain, or residue within the
second protomer. (B) Purified dimeric IR-ECD (IR(αβ0)2) migrates as a single band with an apparent molecular weight of 351 kD on a nonreducing 3–8% Tris-
acetate SDS-PAGE gel as visualized by silver staining. (C) Equilibrium binding to native human insulin in solution was assessed by MST of IR-ECD after Tris-
NTA-RED labeling. An 8xHis-tagged control peptide served as negative control to rule out unspecific binding or interference with the Tris-NTA-RED dye (Fig. S1
H). The normalized fluorescence difference (ΔFnorm) is plotted against ligand concentration. Error bars display standard deviations; n = 3. (D) Front view of the
IR-ECD cryo-EM density map saturated with insulin ligands at 4.3 Å estimated nominal global resolution. Subdomains are colored as in A. (E) Representative 2D
class averages of particles contributing to the reconstruction in D of the IR-ECD exposed to human insulin. Scale bar, 10 nm.
Gutmann et al. Journal of Cell Biology 3
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however, the resolution in this region was too low to finalize
this part of the model (Table S2). This approach allowed us to
calculate contacts and interactions at the atomistic level for the
IR-ECD model, including all loops mentioned above and the
glycans. A contact between two residues was considered to be
established as a stable interaction if the distance between any
pair of atoms in the two residues was ≤3.5 or ≤6 Å, and the
occupancy at this distance was ≥50% of simulation time (Fig. 3
C). In 10 independent 500-ns simulations, the insulin-saturated
ECD displayed increasing flexibility toward the stalks (Fig. S4
B), in line with our cryo-EM data.
The insulin-saturated IR-ECD adopts a T-shape with
converging FnIII-3 domains
In accord with previous data, significant conformational
changes in the insulin-bound IR-ECD are observed with respect
to rigid-body rotations in the apo-IR-ECD (McKern et al., 2006;
Croll et al., 2016; Gutmann et al., 2018; Scapin et al., 2018). The
liganded IR-ECD adopts a T-shaped conformation (Figs. 1 D and
2) similar to the membrane-embedded full-length receptor at
low resolution (Gutmann et al., 2018). The fibronectin domains
come together in a pincer-like fashion (Fig. 2 C) similar to what
has been described for the C-terminally tethered IRΔβ-zipInsFv
complex (Weis et al., 2018). The same FnIII-3 domain loops are
in proximity in our structure and MD simulations as in the
IRΔβ-zipInsFv structure (in particular residues Asp854–His858;
Fig. 3, B and C). This contrasts with the overall completely
different arrangement of the fibronectin domains in the two
structures. Additionally, we observe proximity between the
residues Leu648–Lys652 of ID and Tyr6469–Lys6499 of ID9 do-
mains (Fig. 3, B and C). Thus, the membrane-proximal domains
are capable of interacting in the absence of a C-terminal zipper
element or membrane attachment. The interaction between the
FnIII-3 and FnIII-39 domains further supports the concept that
receptor activation is directly linked to the lateral distance be-
tween transmembrane domains and consequently the relative
orientation of the attached intracellular kinase domains (Kavran
et al., 2014; Gutmann et al., 2018).
Insulin binding sites 1 and 19
Earlier biochemical studies showed that each IR protomer con-
tains two distinct insulin-binding sites, termed site 1 and 2 (site
19 and 29 on the other protomer; De Meyts, 1994, 2015; Schäffer,
1994). The IR-ECD head region of our structural model agrees
well with the IR-ECD cryo-EM structure in complex with two
insulins in site 1/19 (Scapin et al., 2018): the L1-CR-L2 module is
complexed by one insulin and adopts an ∼90° angle with respect
to the [L2-(FnIII-1):L29-(FnIII-19)] module, and insulin 1 interacts
with the L1-αCT9 tandem element and loops of the FnIII-19 do-
main (L19+αCT and FnIII-1 in case of insulin 19; Fig. 2). The mode
of insulin binding to site 1 is essentially the same as in the
previous cryo-EM structures, with details better resolved than
in Scapin et al. (2018) and resolved approximately the same as in
Weis et al. (2018). In addition, our MD simulations largely
confirmed the previously described residue interactions of in-
sulin 1/19 with IR-ECD (Figs. S6 and S7, upper panels). In the
Figure 2. Cryo-EM structure of the ligand-
saturated IR-ECD. (A and B) Orthogonal views
of the cryo-EM map and structure of the IR-ECD
dimer complex. (C) Close-up of the membrane-
proximal FnIII-3 domains. The color code for the
individual domains in all panels is as in Fig. 1; the
four insulin moieties are depicted in red.
Gutmann et al. Journal of Cell Biology 4
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simulations, however, insulin 19 appeared to undergomore overall
conformational fluctuations compared with insulin 1 (Fig. S4 C,
compare RMSD plots for insulin 19 and 1). Along this line, the
C-terminal B-chain of insulin 19 featured higher flexibility com-
pared with insulin 1 (Fig. S4 D).
Structural identification and characterization of insulin
binding to sites 2/29
Contrasting to previous structures, two additional and previ-
ously undescribed density features contacting the FnIII-1 and
FnIII-19 domains were identified in our cryo-EM map (Figs. 1 D
and 2). These features did not correspond to unmodeled regions
of the IR-ECD but could clearly be assigned as additional insulin
molecules (Figs. 2 and 4). The concordance between these den-
sity features and insulin is further supported by the observation
that the map-versus-model correlation coefficient of both head-
and stalk-bound insulins is almost indistinguishable. If any-
thing, it is slightly inferior for the head-bound ligands (Table S1).
These additional insulin molecules were analogously named
insulin 2 and 29, as they employ their site 2 residues to interact
with β-sheets and interstrand loops (Tyr477–Trp489 and
Asp535–Arg554) of the FnIII-1 and FnIII-19 domain, respectively
(Figs. 4 and S5). Among those FnIII-1 residues, Lys484 and Leu552
have been implicated in insulin binding to site 2 in the holor-
eceptor by alanine scanning mutagenesis screens (Whittaker
et al., 2008). Also, insulins 2 and 29 interact with a loop within
the L19 (Asp1519–Glu1549) and L1 domain (Asp151–Glu154), re-
spectively (Fig. S5).
Interestingly, head- and stalk-bound insulins display differ-
ent conformations. Insulin consists of two polypeptide chains,
an A-chain of 21 residues structured into two α-helices separated
by a stretch of extended polypeptide and a B-chain of 30 residues
with a central α-helix (Adams et al., 1969). Insulins 1 and 19were
in the receptor-bound “open” conformation with a detached
B-chain C terminus (including the aromatic triplet Phe B24, Phe
B25, and Tyr B26) that is critical for engaging receptor site 1 (Hua
et al., 1991; Menting et al., 2014). In contrast, insulins 2 and 29
have a “closed” conformation, which corresponds to the
Figure 3. MD simulations of insulin-saturated IR-ECD and interactions of membrane-proximal domains. (A) Orthogonal views of the complete
insulin–IR-ECD starting model used for MD simulations in surface representation. One monomer is color-coded as in Fig. 1 with carbohydrates in purple and the
insulin moieties in red. The second monomer is depicted in white. The disordered ID and C-terminal linker plus tag are shown in cartoon style colored in light
violet and dark gray, respectively. (B) Contact map calculated from our cryo-EM structure showing interactions between ID/FnIII-3 domains of both monomers
with contact cutoffs set to ≤3.5 Å (black) and ≤6 Å (red). (C) Contact occupancies calculated fromMD simulations with the cutoff at 6 Å. Only contacts of ≥50%
occupancy are displayed.
Gutmann et al. Journal of Cell Biology 5
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conformation in solution before IR binding (Hua et al., 1991;
Fig. 4, bottom panels; and Fig. S4 E).
The two newly identified insulins 2 and 29 remained bound to
the receptor during all 10 independent simulations of 500 ns
each (Fig. 5; for direct comparisonwith insulins 1 and 19, see Figs.
S6 and S7). Three key areas of interaction stabilizing insulin
2 (or 29) could be discerned. First, interactions formed between
the central A-chain insulin residues (Ile A10–Glu A17) and
FnIII-1 domain residues (Leu486–Arg488, Asp535–Leu538,
and Asn547–Leu552); second, the interactions between
N-terminal residues of the insulin B-chain (Phe B1–Leu B6)
and FnIII-1 domain residues (Trp551–Arg554); and third, those
between B-chain α-helix residues (His B10–Glu B21) and
FnIII-1 domain residues (Tyr477–Arg488 and Leu552–Arg554).
Interestingly, insulins 2 and 29 display some asymmetry in
their binding (Figs. 5 and 6). In particular, insulin 29 appears to
additionally interact with both ID loops (Gln 672–Ser673 and
Glu6769–Cys6829). Insulin 29–ID interactions were preserved
across all 10 MD simulations. Moreover, insulin 2 appears to
interact with its residues (Gly A1, Glu A4, Gln A5, Thr A8, and
Ser A9) with a single L19 domain loop (Asp1519–Glu1549). In the
case of insulin 29, only Gln A5 is in contact with L1 (Asn152 and
Glu154). Stalk insulins 2/29 mainly pack against β-strands of
FnIII-1/19 domains, which provide a stable interface for binding.
In the case of head-bound insulins, the interaction site is
composed of flexible loops from several domains. Thus, the
binding of insulin 1 and 19 depends on the proper organization
of all required domains and is hence more sensitive to con-
formational variations.
Fluctuations within the insulin conformations during our
simulations are mostly attributed to the flexible A- and B-chain
termini, as indicated in the RMSD plots (Fig. S4, C and D). In
particular, the insulin B-chain nonhelical N and C termini fea-
tured notable flexibility in our simulations (Fig. S4 D). C-terminal
B-chain dynamics were also measured based on center-of-mass
distances between the Cα atoms of the C-terminal residues (Phe
B24–Thr B30) and B-chain α-helix residues (Gly B8, Val B12, and
Leu B15; Fig. S4 E and Table S4). The C-terminal B-chain fluctu-
ations were most pronounced in insulins 2 and 29, which, unlike
insulins 1 and 19, do not engage their B-chain C termini with the
receptor.
Discussion
Our cryo-EM structure of the human IR-ECD in complex with
four insulin molecules offers new insights into the full IR-ECD in
its ligand-saturated state and helps to reconcile a number of
earlier findings to inform an integrated model of insulin–IR
binding and activation (Fig. 7). Insulin binding to the full-length
receptor is characterized by high- and low-affinity binding and/
or negative cooperativity (De Meyts, 1994; Whittaker et al.,
2008). Based on photo-cross-linking and mutagenesis screens,
two distinct molecular surfaces on the insulin molecule have
been identified to interact with two distinct receptor sites (1/19
and 2/29; De Meyts, 1994, 2015). It was furthermore proposed
that insulin cross-links both receptor monomers by binding in a
bivalent manner (De Meyts, 1994, 2015). The interactions of
insulin with site 1 (and 19) on the IR-ECD agree very well with
Figure 4. Binding sites and conformations of insulins bound to IR-ECD. (A–D) The cryo-EM density map and structure in close-up views of the four
insulins and their receptor binding sites are displayed: insulin 1 (A), insulin 19 (B), insulin 2 (C), and insulin 29 (D). Insulin structures are aligned below for
comparison illustrating the open conformation of site-1-bound insulins with a detached C-terminal B-chain segment in contrast to the closed conformation at
site 2. Individual domains in all panels are colored as in Figs. 1 and 2.
Gutmann et al. Journal of Cell Biology 6
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previously described structures of insulin bound to the classic
binding site 1/19 (Menting et al., 2013, 2014; Scapin et al., 2018;
Weis et al., 2018). The classic insulin site 1 residues, which are
widely conserved during vertebrate evolution, participated in
this interaction in our structure and in MD simulations (i.e., Gly
A1–Glu A4, Tyr A19, Asn A21, Gly B8, Ser B9, Leu B11, Val B12, Tyr
B16, Phe B24, Phe B25, and Tyr B26; Figs. 6, S5, S6, and S7).
Insulin bound to site 1 (or 19) simultaneously interacts with
residues from the FnIII-19 (or FnIII-1) domains, similar to the
very recent IR-ECD cryo-EM structures (Scapin et al., 2018;Weis
et al., 2018), supporting the bivalent insulin binding mode pre-
viously proposed (De Meyts, 1994; Schäffer, 1994). The struc-
tural basis for site 2 insulin interactions, however, remained
elusive, and an irreconcilable difference between biochemical
studies and previous cryo-EM data for insulin–IR engagement
persisted.
The biochemically mapped sites 2 and 29 involve residues in
the IR-ECD FnIII-1 domains (De Meyts et al., 1978; Whittaker
et al., 2008; De Meyts, 2015; Ye et al., 2017), which agree well
with our structural data. We could not confirm the site 2/29
residues that were proposed based on an amino acid residue
conservation analysis and the reconstruction of the phylogeny
of the IR family (Renteŕıa et al., 2008). All insulin residues
proposed to be involved in site 2 contacts participated in this
interaction (i.e., Thr A8, Ile A10, Ser A12, Leu A13, Glu A17, His
B10, Glu B13, and Leu B17; Fig. 6).
Functional implications of site 2 and 29 interactions with
insulin
While the stalk-bound insulin molecules in our structure display
a closed conformation reminiscent of insulin conformation in
solution before binding (Hua et al., 1991), the head-bound in-
sulins adopt an open conformation, previously described for
receptor site 1 binding (Xu et al., 2009; Menting et al., 2014;
Weiss and Lawrence, 2018). This suggests that site 2 (or 29) in-
teractions might be important for establishing the initial
ligand–receptor contact and possibly contribute to ligand spec-
ificity, as previously discussed (De Meyts, 2004; Weis et al.,
2018; Xu et al., 2018). The arrangement of sites 1 and 29 in the
apo-IR-ECD crystal structure also implicates sites 2 and 29 as the
sites of first contact. In this structure, sites 2 and 29 are exposed
and solvent accessible, while residues in sites 1 and 19 appear
partially engaged in interactions with the opposite FnIII-2 do-
main (McKern et al., 2006; Whittaker et al., 2008; Croll et al.,
2016). Earlier biochemical findings had already indicated
site 2 as the initial insulin contact site (De Meyts, 2004).
Figure 5. Characterization of the novel insulin binding sites 2 and 29 interactions by MD simulations. Contact occupancies for insulin–IR-ECD inter-
actions derived from our 10 × 500-ns MD simulations with a cutoff of 6.5 Å are depicted for insulin 2 (left) and insulin 29 (right). Only contacts with an
occupancy of ≥50% are displayed. See Figs. S5, S6, and S7 for contact maps comparing all insulin ligands in our cryo-EM structure and MD simulations.
Gutmann et al. Journal of Cell Biology 7
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Evolutionarily ancient vertebrate insulin from hagfish (Myxine
glutinosa) was shown to exhibit anomalous binding behavior,
different from most mammalian insulins. Despite absolute
conservation of all site 1 residues and structural homology,
hagfish insulin displays slow association kinetics, low affinity,
low metabolic potency, and decreased negative cooperativity
(Muggeo et al., 1979; De Meyts, 2004). This was attributed
to variations in site 2 residues Leu A13 and Leu B17, which
contribute significantly to site 2 interactions in our data (Figs. 5
and 6). Analogously, insulin variants carrying alanine re-
placements of those residues display a 20-fold decrease in
initial ligand–receptor association (DeMeyts et al., 1976; De
Meyts and Whittaker, 2002).
Based on the above-described structural and biochemical find-
ings by us and others, a molecular model is envisaged where in-
sulin initially interacts transiently with either of the exposed sites
2 or 29. This may destabilize certain apo-conformation–specific,
inhibitory domain–domain interactions such as the L1:FnIII-29
cross-talk, which in turn permits T-shape specific domain–domain
interactions. The resulting transition states may be similar to those
captured in the cryo-EMdata for unliganded IR-ECD (Fig. S1 I). The
initial capture of insulin by site 2 may also relate to a conforma-
tional change important for ligand engagement with site 1. Indeed,
the C-terminal segments of the insulin B-chains in both insulins
2 and 29were not involved in site 2 interactions at any time in our
MD simulations, but seemed to sample their environment com-
paratively unrestrained. In a situation where site 29 is liganded and
site 1 is still in a transition state, these C termini might be free to
establish contacts with site 1 adopting an open conformation. The
possibility that these segments play a critical role in initiating a
series of conformational changes was suggested very recently
(Weiss and Lawrence, 2018). Finally, the receptor binding sites
1 and/or 19 on the head are fully formed, and insulin interacts with
both receptor monomers in a bivalent manner (De Meyts, 1994,
2015).
Micromolar insulin concentrations reverse negative cooper-
ativity in the full-length cell surface receptor, and all unoccupied
binding sites are believed to become saturated, inducing the so-
called slowly dissociating (Ksuper) state (de Meyts et al., 1973; De
Meyts and Whittaker, 2002; Kiselyov et al., 2009). Under
these conditions, site 2–bound insulins may assume yet another
function by acting as a molecular wedge to prevent L1 from
folding back onto FnIII-1/29, thus stabilizing the T-shaped con-
formation. This view is also supported by our observation of L1/
L19 interacting with insulin 29/2. Strikingly, the stalk-binding
sites are partially asymmetric in our MD simulations: only one
insulin molecule (insulin 29 bound to FnIII-19) appears to interact
with residues of the ID regions of both monomers. It is therefore
Figure 6. Interactions of insulin with the IR-ECD binding sites 1 and 2. (A) Summary of per residue contact occupancies of the four insulins bound to IR-
ECD in the MD simulations. The contact occupancies are encoded by shades of red. Only contacts of ≥50% occupancy are displayed. Residues shown previously
to contribute to interactions with IR-ECD site 1 and site 2 in biochemical experiments are highlighted in blue and green, respectively. The secondary structure of
human insulin is drawn schematically above the contact map (based on PDB 3I3Z). (B) Contact occupancies color-coded as in A are plotted on the structural
models of the four insulins bound to the IR-ECD. (C) This is juxtaposed with coloring of biochemically predicted site 1 and site 2 residues in blue and green,
respectively.
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tempting to speculate whether this asymmetry-inducing inter-
action is critical for generating negative cooperativity in the cell
surface receptor. Such an interaction would likely influence the
positioning of the αCT/αCT9 helices critical for high-affinity
binding and for cross-talk with the stalks. Another potentially
cross-talking element might be the FnIII-1 domains, which fea-
ture one of the interprotomer disulfide bonds and contribute to
binding of insulin to sites 1/19 and 2/29 (Fig. 4).
It is not known whether initial insulin docking at the re-
ceptor induces a conformational change or whether the receptor
transiently adopts various conformations allowing the ligand to
engage, or both. The high structural heterogeneity of the un-
liganded ECD observed here (Fig. S1 I) supports the view that the
insulin-free IR adopts various transition states and thereby
samples its environment. Even though this interpretation is in
line with earlier in silico predictions, the precise contribution of
distinct receptor conformations to signaling remains to be un-
derstood in detail (Kiselyov et al., 2009). This is not to imply that
the four-insulin–bound state reported here necessarily corre-
sponds to the most prevalent, physiologically active IR confor-
mation. However, this structure exhibits all possible binding
sites, including those important for initial contact, albeit with
possibly differing precise binding modes in the transition states
(Fig. 7).
Interestingly, we observed higher conformational fluctua-
tions in insulin 19 comparedwith insulin 1 in ourMD simulations
(Fig. S4 C). This behavior is also reflected in overall weaker
C-terminal B-chain contacts between insulin 19 and the receptor,
which are critical for binding (Fig. 6). We then decided to
reevaluate our cryo-EM dataset, which led to the identification
of a second, minor 3D class with a potentially distinct ligand
binding site occupancy (Fig. S2, “intermediate state”). This
small, but stable, 3D class of particles captures a distinct con-
formation of the receptor with at least two insulins bound to
sites 1 and 29, with the membrane proximal FnIII-3 domains
remaining converged (Fig. S8 B). The reconstruction is not as
highly resolved compared with the four-insulin–bound state
(5-Å global resolution estimate according to the 0.143 FSC
cutoff criterion) and comprises merely 1.7% of the initial
particles. Surprisingly, however, the domains in the receptor
head lacking insulin are strikingly tilted. An additional den-
sity proximal to site 2 is consistent with a bound insulin in
both size and shape, but is insufficiently resolved to exclude it
being portions of the receptor (e.g., αCT peptide). As such, we
cautiously assign the “intermediate state” reconstruction as a
two- or three-insulin–bound structural intermediate. This
second 3D reconstruction provides evidence that even at the
saturating insulin concentration used here, the receptor
adopts various liganded states.
Ligand occupancy and implications for ligand selectivity
Our finding that the human IR binds up to four insulin mol-
ecules simultaneously (Fig. 7) provides a hint as to how ligand
specificity and selectivity might be realized in the cellular
context, considering that a single receptor exhibits distinct
responses to different ligands. In humans, the relevant ligands
are insulin-like growth factor 1 and 2, in addition to insulin.
Further examples of ligand heterogeneity are the homologous
invertebrate insulin-like receptors. Drosophila melanogaster ex-
presses 7 insulin-like peptide ligands for a single insulin-like
receptor, while Caenorhabditis elegans even has 40 insulin-like
peptides that have been genetically identified and shown to act
in a combinatorial manner to coordinate various physiological
processes (Garofalo, 2002; Fernandes de Abreu et al., 2014). This
diversity emphasizes how important careful examinations of
even the subtlest asymmetries within the receptors are, as they
likely are significant for high-affinity ligand binding, coopera-
tivity, ligand selectivity, and signaling outcome, as shown for the
EGF receptor (Alvarado et al., 2010; Freed et al., 2017). For this
reason, we refrained from imposing any symmetry in our re-
constructions, thereby allowing us to unequivocally identify
asymmetries within binding pockets, the ID domains, and the
fibronectin stalks, all of which are likely to constitute functional
features of the receptor.
Figure 7. Schematic models of unliganded and liganded transition states for which complete IR-ECD structures have been reported. (A) Apo-IR-ECD
(PDB 4ZXB; Croll et al., 2016). (B) Singly liganded IRΔβ-zipInsFv (PDB 6HN4 “lower” membrane-proximal part and PDB 6HN5 “upper” membrane-distal part;
Weis et al., 2018). (C) Unknown intermediate states. (D) The four-insulin–saturated IR-ECD structure determined in this study. The subdomains are color-
coded as in Fig. 1, and insulins are depicted in black with the respective binding site indicated.
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After depositing our manuscript on the four-insulin:IR-ECD
structure to bioRxiv (Gutmann et al., 2019 Preprint) and during
the revision of this manuscript, an additional cryo-EM studywas
published (Uchikawa et al., 2019). The authors reported a single
structure of the ECD of a detergent-solubilized full-length IR in
dodecylmaltoside micelles. By enforcing C2 symmetry, this re-
construction reached a global resolution estimated as 3.2 Å. The
structure confirms the “saturated” T-shaped four-insulin–bound
ECD structure seen here, especially with regard to the receptor
head. However, the imposed C2 symmetry masks the intricacies
of binding asymmetry that is evident in our map and simu-
lations. Furthermore, our intermediate state map demonstrates
that a change in occupancy is concomitant with a conforma-
tional change. In turn, this raises questions concerning the
utility of symmetry expansion for examining ligand occupancy.
Future work is required to study the full-length receptor in a
membrane context; in particular considering the well-
documented detergent bias (varying with the detergent to pro-
tein ratio) on the receptor leading from hypersensitization to
inhibition (Leray et al., 1992; Delle Bovi and Miller, 2017). Fur-
ther concerns persist, as previous studies dating back to the
1990s reported Y- or T-like structures already for detergent-
solubilized full-length IR, which did not display conforma-
tional changes upon insulin addition (Christiansen et al., 1991;
Tranum-Jensen et al., 1994; Woldin et al., 1999). A C2-
symmetrized reconstruction of a detergent-solubilized IR in
complex with gold-labeled insulin determined by CryoSTEM, on
the other hand, suggested an altogether different structure (Luo
et al., 1999), which we cannot easily reconcile with our model
and other recent structures (Scapin et al., 2018; Weis et al., 2018;
Uchikawa et al., 2019). The in vitro reconstitution of full-length
IR in artificial membrane systems and thorough detergent re-
moval were key for capturing the IR in a ligand-sensitive apo-
conformation, which underwent large rigid body rotations into
the T-shape in an insulin dose-dependent manner (Gutmann
et al., 2018).
Outlook
Although insulin replacement remains an essential therapy, it is
still hampered by the inability of exogenously administered
insulins to recapitulate the full spectrum of physiological insulin
action (Jiráček and Žáková, 2017). A thorough understanding of
the molecular details of ligand–IR activation is a prerequisite for
the development of specific agonists as well as antagonists.
Ligand titration with insulin, other agonists, or antagonists will
help to capture the initial insulin docking and various confor-
mational transition states of the receptor. Furthermore, in light
of recent structural insights, the current mathematical binding
models for insulin binding require reevaluation. TheMD system
reported here provides a valuable resource for engineering and
testing novel ligands in silico.
We, and others, have suggested that the transmembrane
signaling mechanism of the IR relies on the control of the dis-
tance between the transmembrane domains exerted by its ECD
(Whittaker et al., 1994; Kavran et al., 2014; Gutmann et al., 2018).
Similar to the IR, the distance between the membrane-proximal
regions of the structurally related mitogenic insulin-like growth
factor-1 receptor ECD is reduced from ∼115 to ∼67 Å in its un-
liganded form (Xu et al., 2018). This implies that the fine tuning
of transmembrane domain positioning and orientation may be
an intricate detail of ligand selectivity and cell signaling out-
comes via allosteric domain coupling across the membrane.
Therefore, integrating membrane lipid composition and lipid–
protein interactions at the next level of reconstruction and
analysis will indispensably contribute to a complete under-
standing of receptor function (Coskun and Simons, 2011; Endres
et al., 2014; Kaszuba et al., 2015) and improved pharmacological
targeting.
Materials and methods
Cloning and production of IR-ECD
A gene encoding human IR-ECD (IR signal sequence followed
by residues 1–917 of the mature IR isoform A; UniProt entry
P06213-2) followed at its C terminus by the 25-residue sequence
SSGPSGSHHHHHHHHGSLEVLFQGP (i.e., a protease-resistant
linker, the 8xHis tag, and the human rhinovirus 3C protease
cleavage site) and a tandem-affinity purification tag (Rigaut
et al., 1999) was cloned into the pTT6 vector, called pTT6-
IRA.ECD-8xHis-TAP, for transient expression in mammalian
cells. The pTT6 vector, which was derived from pTT3 (Durocher
et al., 2002), featuring a Kozak sequence and amodifiedmultiple
cloning site, was kindly provided by the Protein Expression
Purification and Characterization facility at the Max Planck
Institute of Molecular Cell Biology and Genetics, Dresden, Ger-
many. FreeStyle HEK293F cells (R79007, Thermo Fisher Scien-
tific; RRID:CVCL_D603) were maintained in suspension in
protein-free, chemically defined FreeStyle 293 Expression
Medium (R79007, Thermo Fisher Scientific) supplemented
with 1× penicillin/streptavidin (15140122, Thermo Fisher Sci-
entific) at 90 rpm, 8% CO2, 37°C. Before transfection, the me-
dium was replaced with fresh antibiotic-free medium. 2 liters
of FreeStyle HEK293F cells were transiently transfected with
pTT6-IRA.ECD-8xHis-TAP at a density of 2 × 106 cells/ml by
transfection with 2 mg endotoxin-free DNA precomplexed with
polyethylenimine (at a ratio of 5:1 wt/wt to DNA; Longo et al., 2013).
Upon transfection, cells were maintained for 64 h at 31°C, 8% CO2,
90 rpm. The conditioned medium was harvested by pelleting the
cells at 300 g, 10 min, 25°C. Cells could be maintained for three
more days in fresh medium for a second round of purification.
Affinity purification of IR-ECD
Human IR-ECD (i.e., IR(αβ0)2) was purified from a 2-liter batch
of conditioned medium. The medium was cleared by centrifu-
gation at 2,500 g, 10 min, 4°C, and the supernatant was then
allowed to bind to 4 ml IgG Sepharose beads for 3 h at 4°C under
constant agitation, and then loaded onto a 2.5 × 20-cm Econo-
Column glass chromatography column (7372522, Bio-Rad Labo-
ratories). The flow-through was collected and reloaded onto the
column. Running buffers were all based on Hepes-buffered sa-
line (HBS; 50 mM Hepes, pH 7.5, and 150 mM NaCl), and all
purification steps were performed at 4°C. The IgG Sepharose
beads were washed with 10 column volumes (CV) of running
buffer (RB; 150 mM NaCl, 50 mM Hepes, pH 7.5, and 5% vol/vol
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glycerol), 2 CV RB-ATP (RB + 5 mM ATP and 10 mM MgCl2),
2 CV RB-EDTA (RB + 20 mM EDTA), and then 20 CV elution
buffer (RB + 15% vol/vol glycerol). For elution, IgG beads were
incubated with glutathione S-transferase–tagged human rhino-
virus 3C protease (50 µg protease per ml beads; provided by the
Max Planck Institute of Molecular Cell Biology and Genetics) for
TAP tag cleavage overnight at 4°C. After protease cleavage, IR-
ECD was eluted in one step with 2.5 CV elution buffer. To re-
move coeluting protease and other impurities, the eluate was
incubated with 1 ml Ni-NTA Superflow beads (Qiagen, 30430)
for 3 h at 4°C on a rotating wheel for immobilized metal ion
affinity chromatography (IMAC). The slurry of resin was then
loaded onto a disposable conical 0.8 × 4-cm polypropylene col-
umn (Bio-Rad Laboratories). The flow-through was collected
and reloaded onto the column. The resin was washed with 10 CV
HBS including 10 mM imidazole (3899.3, Carl Roth) and eluted
with HBS including 280mM imidazole in 1-CV fractions. The pH
of the wash and elution bufferswas adjusted to 7.5. IMAC elution
fractions were analyzed by reducing SDS-PAGE using precast
NuPAGE 4–12% Bis-Tris gels (Thermo Fisher Scientific) with
1× MOPS buffer (Thermo Fisher Scientific) and subsequent
Coomassie Brilliant Blue G-250 staining (Fig. S1 A).
For biochemical studies, IMAC elution fractions were directly
subjected to gel filtration using a Superdex 200 Increase 10/300
GL column equilibrated in HBS at a flow rate of 0.5 ml/min at
room temperature to separate dimeric IR-ECD from monomeric
IRαβ0. The peak fraction containing IR-ECD was stored at 4°C
until further use, within 72 h. The apparent molecular weight of
IR-ECD was estimated in SDS-PAGE with 3–8% Tris-Acetate gels
(Life Technologies) using HiMark unstained protein standards
(Thermo Fisher Scientific; Fig. S1). The IR-ECD concentration
was estimated using amolar extinction coefficient for IR(αβ0)2 of
280,260 M−1 cm−1 at 280 nm absorbance (as calculated by Ex-
PASy/ProtParam [Gasteiger et al., 2003] assuming one free thiol
group per monomer [Chiacchia, 1991; Sparrow et al., 1997]). This
concentration estimate was confirmed once with a BCA protein
assay (Thermo Fisher Scientific).
For cryo-EM studies, IMAC elution fractions containing most
concentrated IR-ECD were immediately desalted after immobi-
lized metal affinity chromatography elution using disposable
8.3-ml Sephadex G-25 PD-10 desalting columns, concentrated to
3 µM in Amicon Ultra-0.5 ml ultrafiltration units with Ultracel-
100 membranes (Merck Chemicals), and kept on ice until fur-
ther use within 24 h. The concentrated protein was gel-filtrated
using a Superdex 200 10/300 GL column equilibrated in HBS at
a flow rate of 0.5 ml/min and 4°C (GE Healthcare). The peak
fraction containing IR-ECD was immediately used for cryo-EM
sample preparation.
MST to determine insulin binding to IR-ECD
Recombinant human insulin was purchased from Sigma-Aldrich
(I2643, lot SLBR9404V, expressed in yeast, 99% purity by HPLC,
0.4% zinc) and resuspended in 5mMHCl at 3 mg/ml (20252.244,
VWR Chemicals). The purity of insulin was confirmed by mass
spectrometry under denaturing conditions where only mono-
meric and dimeric insulin with a mass of 5803.651 ± 0.003
Daltons was detectable, corresponding to the expected mass of
insulin with all three disulfide bridges formed. Under native
conditions, as expected, additional peaks corresponding to
higher insulin oligomers appeared.
Insulin binding to IR-ECD was analyzed by MST. First, IR-
ECD was diluted to a final concentration of 100 nM in HBS-T
(HBS, pH 7.5, and 0.05% Tween-20) and labeled with 25 nM tris-
nitriloacetic acid conjugated to NT647 (red tris-NTA; Lata et al.,
2005; Bartoschik et al., 2018), which was a kind gift of Jacob
Piehler (University Osnabrück, Osnabrück, Germany). A label-
to-IR(αβ0)2 molar ratio of 1:4 was chosen to circumvent inter-
ference of free dye. The reaction was incubated for 30min in the
dark at room temperature and was subsequently centrifuged at
14,000 g for 10 min at 4°C.
For ligand binding assays, a 100-µM stock solution of re-
combinant human insulin in 5 mM HCl was diluted to a con-
centration of 5 µM inHBS-T. A serial dilutionwas prepared with
ligand binding buffer (i.e., HBS with 25 µM HCl). 10 µl of the
diluted ligand was incubated with 10 µl of 20 nM IR-ECD
overnight at 4°C. Thus, the final assay concentrations were 10
nM IR-ECD and 2.5 nM red tris-NTA.
MST was performed in standard capillaries (MO-K022,
Nanotemper Technologies) on a Monolith NT.115Pico instrument
(Nanotemper Technologies) using the Pico-RED detector with
30% light-emitting diode power at 25°C. Data were analyzed
with MO.Affinity Analysis 2.2.7 software (NanoTemper Tech-
nologies). The integral of thermophoresis traces from 1 to 20 s
on-time was used for binding affinity determination, and the
normalized fluorescence difference ΔFnorm was plotted against
ligand concentration for dose–response plots. To determine Kd
values, nonlinear regression (one-site binding) was performed
using Prism version 7.0 for Windows (GraphPad Software).
A concentration range, within which insulin did not appear
to interact nonspecifically with the labeling reaction or with the
dye itself, was determined by titrating insulin against a red tris-
NTA–labeled control peptide (comprising an 8xHis tag and part
of the HRV3C cleavage site, i.e., 2HN-HHHHHHHHKLEVLF-
CONH2).
Thermal stability by nano–differential scanning fluorimetry
(nanoDSF)
To further characterize IR-ECD and to monitor its stability, a
thermal unfolding assay was performed applying label-free,
low-volume nanoDSF. IR-ECDwas diluted to 500 nM inHBS and
incubated with or without 50 µM insulin for 1 h on ice in a
volume of 22 µl. Samples were loaded into nanoDSF Grade
Standard capillaries (PR-C002, NanoTemper Technologies) in
duplicate and transferred to a Prometheus NT.48 instrument
(NanoTemper Technologies). Thermal unfolding was detected
by recording the intrinsic tryptophan fluorescence (emission
ratio at 350 and 330 nm) during heating in a linear thermal ramp
(1°C/min; 20°C to 95°C) with an excitation power of 100%.
Cryo-EM grid preparation and imaging
Peak fractions at a final Abs280nm of ∼0.4 (∼1.4 µM) were in-
cubated for ∼30min at 4°C with or without recombinant human
insulin supplementation at 28× molar excess (∼40 µM final
concentration). 4 µl of these samples were applied to glow
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discharged (2.2 × 10−1 mbar for 2 × 20 s) Quantifoil holey carbon
grids (R2/1, 200 mesh, Quantifoil). The grids were plunge vit-
rified in a liquid ethane/propane mix using a Vitrobot Mark IV
at 4°C and 95% humidity. Cryo-EM data were collected on a FEI
Titan Krios microscope operated at 300 kV, equipped with a
postcolumn Gatan energy filter and a K2 Summit direct detector
operating in counting mode. A total of 8,882 movies were re-
corded at a nominal magnification of 130,000× that corresponds
to 1.059 Å/pixel at the specimen level using SerialEM
(Mastronarde, 2005). The total exposure of 55 e−/Å2 at the
specimen level was evenly distributed over 51 frames during
10.2 s. The preset target defocus range was 0.5–3.5 µm. The
sample preparation and data collection strategies for the apo-
IR-ECD samples were very similar except that no insulin was
used for grid preparation. These data were collected with a total
exposure of 59 e−/Å2, spread over 51 frames and 10.2 s. The
target defocus ranged from 0.5 to 3.5 µm. No stage pretilt was
used for either of the two datasets.
Cryo-EM data acquisition and processing
The RELION-3.0 implementation of MotionCor2 (Zheng et al.,
2017) was used to correct for beam-induced sample motions and
radiation damage. The summed and dose-weighted micrographs
were used for further processing. Particles were selected using
Gautomatch version 0.56 (https://www.mrc-lmb.cam.ac.uk/
kzhang/Gautomatch/). CTF parameters were determined us-
ing Gctf (Zhang, 2016). If not stated otherwise, all further
processing was performed in RELION v2.1 or v3.0 (Kimanius
et al., 2016; Zivanov et al., 2018). In the case of the insulin-
bound structure, initial analysis of particles picked without
templates yielded a 3D reconstruction using as template a 60-Å
low-pass filtered initial model generated by the stochastic
gradient descent implementation of RELION v2.1 (Kimanius
et al., 2016; compare Fig. S2 for a graphical overview of the
processing routine). Low-pass filtered projections of this re-
construction were used as templates for template-based parti-
cle picking on all micrographs. This resulted in 2,997,079
particle candidates. The particle stack was cleaned up by un-
supervised 2D classification in subsets of ∼120,000 particles.
Subsequently, the data were further processed in ∼120,000
particle chunks in 3D classification with the first reconstruc-
tion as a 60-Å low-pass filtered starting model. The resulting
cleaned dataset of 326,257 particles reached a nominal global
resolution of 4.9 Å after 3D refinement and postprocessing.
Bayesian polishing in RELION v3.0 (Zivanov et al., 2018) was
used to correct further for beam-induced motion and radiation
damage, improving the quality of the map to a final apparent
resolution of 4.3 Å. The global resolution estimates of the ob-
tained reconstructions are quoted as good proxies for the
overall relative quality of the individual reconstructions, fully
acknowledging the differences in local resolution estimates as
well as the anisotropy of the data. The angular distribution of
particles contributing to this map is shown in Fig. S3, C and D,
and the FSC curve of the masked independent half-maps in Fig.
S3 E. The rotation versus tilt angle plot in Fig. S3 C was created
by binning the angular assignments of all particles contributing
to this reconstruction in 3° × 1.5° bins, followed by plotting the
resulting distribution using the Tidyverse collection of R
packages (https://www.tidyverse.org/). The local resolution
estimate in Fig. S3 F was calculated with the local resolution
routine implemented in RELION v3.0 (Zivanov et al., 2018).
The minor class we termed “intermediate state,” which is
described in Figs. S2 and S8, was processed in a similar way as
the “saturated state.” After the above-described classification in
∼120,000 particle chunks, 50,079 particles were subjected to 3D
refinement focused on the ECD “head.” This reconstruction
reached a nominal global resolution of 5.0 Å (according to the
0.143 FSC cutoff criterion) after Bayesian polishing in RELION
v3.0 (Zivanov et al., 2018), a further 3D refinement step of the
whole ECD as well as map filtering and sharpening. The rotation
versus tilt angle plot in Fig. S8 C was created by binning the
angular assignments of all particles contributing to this recon-
struction in 3° × 3° bins, followed by plotting the resulting dis-
tribution using the Tidyverse collection of R packages.
The data of the ligand-free IR-ECD sample were processed
using an approach similar to that outlined above. Since the at-
tempts at 3D reconstruction never yielded resolutions in the
subnanometer range, only 2D class averages are shown.
Model building and refinement
A nonglycosylated IR-ECD model with four insulins was
constructed initially for fitting into the cryo-EM density map.
This model was based on the previously published partial
insulin-bound IR-ECD (PDB 6CEB, including the two head-
bound insulins 1 and 19). The L1 and L19 domain residues
H144 were modified to Y144 to match the IR construct used
here (Uniprot P06213-2). Regions that were not resolved in
PDB 6CEB were added as described in the following. As reli-
able starting models for the FnIII domains, we included the
respective coordinates from PDB 4ZXB (Croll et al., 2016) in
the structure. Additionally, we constructed tentative models
of the IDα loops (chain α and α9 residues 651–687) using
MODELLER (Eswar et al., 2006) and included them in the
structure, since we observed some incohesive density features
for these regions. The stalk-bound insulins 2 and 29 were
modeled based on the structure of porcine insulin (PDB 4INS;
Baker et al., 1988). To match the human insulin sequence, the
insulin B-chain C terminus residue was mutated from A30 to
T30. The model is thus consistent with the complete human
IR-ECD (UniProt P06213-2) and human insulin sequences
(UniProt P01308) and matches the experimental constructs
used in this study.
As a first step in the fitting procedure, global, rigid body
docking of the resulting nonglycosylated IR-ECD in complex with
four insulins into the density map was performed in UCSF Chi-
mera (Pettersen et al., 2004). To locally improve the model, we
used a combination of flexible fitting methods including the real-
space structure refinement program DireX (Wang and Schröder,
2012), followed by the simple relax protocol in torsional space in
Rosetta (Fleishman et al., 2011; Conway et al., 2014). As a last step,
the cysteines involved in intra- and interchain dimer bonds as
well as specific β-strands of the FnIII-3 domains were directed
into selected regions of the densitymap by interactiveMD flexible
fitting (Trabuco et al., 2009; McGreevy et al., 2016).
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After completion of the initial fitting routine outlined above,
the structure was subjected to several rounds of iterative real-
space refinement in phenix.refine (Afonine et al., 2018) and
manual adjustment in Coot (Emsley et al., 2010). Progress in
modeling was monitored via the map-to-model correlation co-
efficients, geometry indicators, and the map-versus-model FSC
(see Table S1). Structure images were created in PyMOL2 (Py-
MOL Molecular Graphiscs System, Schrödinger) and ChimeraX
(Goddard et al., 2018). The refined model is deposited in PDB
(accession number 6SOF) and is referred to in the main text as
“cryo-EM structure.”
Since our reconstruction did not produce clear density fea-
tures for the Arg-Lys-Arg-Arg residues (furin cleavage site), the
disordered IDβ region, and the residual C-terminal purification
tag sequence, these parts are not included in the refined struc-
ture (see also Table S2). However, for completeness, they are
included in the model used in MD simulations described below.
We decided to include the modeled side chains in our IR-ECD
structure bound to four insulins (PDB 6CEB), since it is our belief
that the resulting model most closely approximates our experi-
mental cryo-EM data. In our view, this is justified because por-
tions of the reconstruction are resolved to ∼4 Å (especially the
core of the head domain; see local resolution estimate in Fig. S3 F),
at which point individual bulky side chains become discernible. In
addition, even at lower resolution, side chains potentially con-
tribute to the signal in the particle images. This is supported by
the model-to-map correlation coefficients being lower in the ab-
sence of side chains compared with the deposited model (e.g.,
CCmask of 0.63 for no-side chains vs. 0.72 with side chains model).
However, we strongly advise readers against interpreting side
chain–level interactions in our model, as there is insufficient basis
for such interpretations from our cryo-EM density.
Atomistic MD simulations
For atomistic MD simulations, we completed the structure re-
fined against the EMmap described above by adding all the loops
invisible in our density map (i.e., the furin cleavage site,
residues 720–723), the disordered and highly glycosylated
N-terminal region of the IRβ subunit (residues 724–756), and
the residual C-terminal purification tag sequence (SSGPSGSH
HHHHHHHGSLEVLFQ). All of these additional loops and
regions were built using MODELLER (Eswar et al., 2006).
Additionally, based on the glycan composition defined previ-
ously (Sparrow et al., 2007, 2008), we added 17 N-linked and
6 O-linked glycans on each monomer (Table S3) using the
doGlycans tool (Danne et al., 2017). The OPLS-AA force field
(Kaminski et al., 2001; Danne et al., 2017) was used for pro-
teins, glycans, and ions. The glycosylated IR-ECD was energy-
minimized in vacuum using the steepest descent algorithm to
remove any steric clashes due to overlapping atoms. The
energy-minimized structure was then solvated using the
TIP3P water model (Jorgensen et al., 1983) in a box of 21 nm3.
The solvated structure was neutralized with an appropriate
number of Na+ counterions complemented by 150 mM NaCl to
match experimental buffer and salt concentration. The system
consisted of 924,775 atoms in total. The resulting structural
model of the IR-ECD is referred to as “MD model” in the text.
Before MD simulations, the system was again subjected to
energy minimization followed by 50-ns equilibration under
NVT (constant particle number, volume, and temperature)
conditions at 298 K using the v-rescale thermostat (Bussi et al.,
2007) with a time constant of 0.1 ps. At this stage, the IR-ECD
and the insulin backbone atoms were position-restrained with a
force constant of 1,000 kJ mol−1 nm−2. Next, equilibration
of the system was continued under NpT (constant particle
number, pressure, and temperature) conditions using isotropic
Parrinello–Rahman pressure coupling (Parrinello and Rahman,
1980, 1981, 1982) with a time constant of 2 ps over a period of 50
ns, with reference pressure set to 1 bar and isothermal com-
pressibility to 4.5 × 10−5 bar−1. The IR-ECD and the insulin
backbone atoms were again position-restrained with a force
constant of 500 kJ mol−1 nm−2. The resulting structure is re-
ferred to as “starting MD model” throughout the text. Electro-
static interactions were calculated by the particle mesh Ewald
method (Darden et al., 1993; Essmann et al., 1995) using 1.0 nm
for the cutoff of the real space component. The same cutoff
distancewas set for van derWaals interactions together with the
LINCS algorithm (Hess et al., 1997) for all bonds. Periodic
boundary conditions were applied in all three dimensions. The
final production run for 500 ns was performed after removal of
all position restraints, and the rest of the input parameters were
the same as those used under NpT equilibration simulations. All
MD simulations were performedwith an integration time step of
2 fs using the GROMACS 4.6 simulation package (Hess et al.,
2008), and the output trajectory and energies were saved ev-
ery 100 ps. For reproducibility of the results, 10 repeats (500 ns
each) were performed.
For the analyses, GROMACS tools and in-house built scripts
were used. Contact maps were built with the g_distMat analysis
tool. A contact for a given pair of residues was considered to be
established if the minimum distance between any atoms in the
two residues was either ≤3.5 Å or ≤6 Å. RMSD analysis was per-
formed for backbone atomswith respect to the startingMDmodel.
The final 100 ns from each of the 10 trajectories were used to
generate residue contact occupancy maps. MDmovies and figures
were prepared using VMD (Humphrey et al., 1996) and PyMOL2.
Data availability
The cryo-EM density maps and structural model of the
4:1 insulin–IR-ECD complex developed in this study are avail-
able from the Electron Microscopy Data Bank (EMD-10273) and
Protein Data Bank (PDB 6SOF), respectively. The cryo-EM
density map for the IR-ECD bound by several insulins in an
intermediate state is available from the Electron Microscopy
Data Bank (EMD-10311).
Online supplemental material
Fig. S1 illustrates the IR-ECD purification, the analysis of insulin
binding, and 2D class averages of apo-IR-ECD. Figs. S2 and S3 give
an overview on cryo-EM data collection and processing. Fig. S4
demonstrates asymmetries in our cryo-EM structure and flex-
ibilities or fluctuations of IR-ECD and its insulin ligands during our
MD simulations. Figs. S5, S6, and S7 provide contact and occupancy
maps based on the cryo-EM structure or MD simulations. Fig. S8
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gives an overview of the cryo-EM data processing for our 3D re-
construction of the intermediate state IR-ECD bound to several
insulins. Table S1 provides a summary of the cryo-EM data col-
lection and model quality indicators. Table S2 summarizes all
residues included or absent from the insulin–IR-ECD cryo-EM
structure. The glycan composition of IR-ECD in our MD simula-
tion model is in Table S3. Table S4 provides center-of-mass dis-
tance measurements between insulin B-chain C-terminal and
B-chain α-helix residues for our 10-MD simulations.
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